Navigation Links
NeoGenomics Awarded $374,000 in R&D Grants from the US Government

NeoGenomics Awarded $374,000 in R&D Grants from the US Government -- FT. MYERS, Fla., Nov. 4, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Domestic Policy Click to view news release full screen  

NeoGenomics Awarded $374,000 in R&D Grants from the US Government


FT. MYERS, Fla., Nov. 4, 2010 /PRNewswire-FirstCall/ --- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported that it had been awarded two research and development grants totaling $374,479 from the US government under HR: 3590 - Patient Protection and Affordable Care Act (the "Act").

Under the Act, $1 billion was earmarked for qualifying therapeutic discovery projects that show the potential to produce new cost saving therapies, create U.S. jobs, increase the country's competiveness, or significantly advance the goal of curing cancer within the next 30 years.

NeoGenomics submitted two applications under this program for expenses incurred in connection with its new test development activities.  NeoGenomics was awarded $244,479 under the first application, the maximum allowable award per application, and $130,000 under the second application.Doug VanOort, NeoGenomics' Chairman and CEO, said, "We are very pleased to have been awarded these grants.  They are an important recognition of the work we are doing to bring new cancer diagnostic tests to the market.  We expect to receive the funds sometime during the month of November."

About NeoGenomics, Inc.NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit  

For more news and information on NeoGenomics, please visit where you can find a fact sheet on the company, investor presentations, and more.  Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at or from the American Microcap Institute at

Forward Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.


SOURCE NeoGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010
2. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
3. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
4. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
5. Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
6. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
7. Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program
8. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
9. Champions Biotechnology Awarded $1.46 million in Grants
10. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
11. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):